Jennifer Lord-Bessen, Esther Natalie Oliva, Mrudula B Glassberg, Hong Xiao, Jessica Jordan, Gale Harding, Ahmed Hnoosh
{"title":"Review, conceptual model, and gap analysis of transfusion burden in hematological diseases.","authors":"Jennifer Lord-Bessen, Esther Natalie Oliva, Mrudula B Glassberg, Hong Xiao, Jessica Jordan, Gale Harding, Ahmed Hnoosh","doi":"10.1080/17474086.2026.2667750","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hematological diseases affect millions of people worldwide, and many of these patients require blood transfusions. Although the potential adverse clinical outcomes associated with transfusions are well documented, the patient perspective of transfusion burden in hematological diseases is not. This perspective is critical, as health-related quality of life scores alone cannot fully capture patients' experiences.</p><p><strong>Areas covered: </strong>A comprehensive review was conducted to understand the patient perspective of transfusion burden in hematological diseases. This study included a targeted literature review of peer-reviewed articles conducted in Embase and MEDLINE from January 2012-September 2024 (stage 1), a preliminary conceptual model (stage 2), a review of patient-reported outcome measures (PROMs) included in clinical trials and label claims (stage 3), and a gap analysis of existing PROMs (stage 4).</p><p><strong>Expert opinion: </strong>This study identified four key concepts and two existing PROMs that were relevant to transfusion burden in hematological diseases. Transfusions impact patients economically, physically, socially, and emotionally. The study identified an unmet need: existing PROMs lack specificity to transfusion burden, lack generalizability to all hematological diseases, and do not reflect all four key concepts identified. A new PROM is needed to better understand the patient perspective of transfusion burden in hematological diseases.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"767-778"},"PeriodicalIF":2.8000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2026.2667750","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Hematological diseases affect millions of people worldwide, and many of these patients require blood transfusions. Although the potential adverse clinical outcomes associated with transfusions are well documented, the patient perspective of transfusion burden in hematological diseases is not. This perspective is critical, as health-related quality of life scores alone cannot fully capture patients' experiences.
Areas covered: A comprehensive review was conducted to understand the patient perspective of transfusion burden in hematological diseases. This study included a targeted literature review of peer-reviewed articles conducted in Embase and MEDLINE from January 2012-September 2024 (stage 1), a preliminary conceptual model (stage 2), a review of patient-reported outcome measures (PROMs) included in clinical trials and label claims (stage 3), and a gap analysis of existing PROMs (stage 4).
Expert opinion: This study identified four key concepts and two existing PROMs that were relevant to transfusion burden in hematological diseases. Transfusions impact patients economically, physically, socially, and emotionally. The study identified an unmet need: existing PROMs lack specificity to transfusion burden, lack generalizability to all hematological diseases, and do not reflect all four key concepts identified. A new PROM is needed to better understand the patient perspective of transfusion burden in hematological diseases.
期刊介绍:
Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.